Johnson & Johnson announced sales of $16.1 billion for the first quarter of 2012, a decrease of 0.2% as compared to the first quarter of 2011. Operational results did increase 1%, and the negative impact of currency was 1.2%. Domestic sales declined 5.1%, while international sales increased 4.1%, reflecting operational growth of 6.4% and a negative currency impact of 2.3%.
The company did report its Neutrogena brand contributed positively to operational results for its Worldwide Consumer division sales, which came in at $3.6 billion for the first quarter. International sales of oral care products also were strong, but the division’s sales numbers represented a decrease of 2.4% versus the prior year consisting of an operational decline of 0.6% and a negative impact from currency of 1.8%. Domestic sales decreased 2.2%, and international sales decreased 2.5%, which reflected an operational increase of 0.4% and a negative currency impact of 2.9%.
“We continue to bring meaningful innovations to our customers through the strong performance of our recently launched products,” said William C. Weldon, J&J chairman and CEO. “The dedication of the people of Johnson & Johnson gives me great confidence in the prospects of our business to deliver sustainable growth well into the future.”